Mode
Text Size
Log in / Sign up
Phase 4 N=71 Treatment

The 3DKnee™ System: A Post-Market Study

Osteoarthritis · Rheumatoid Arthritis · Post Traumatic Arthritis · Varus Deformity · Avascular Necrosis

Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Mar 2011
Primary outcome: Primary: Knee Society Score Evaluation — 82.9 Average Knee Rating Score

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
3DKnee (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Encore Medical, L.P.
Primary completion
Oct 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Knee Society Score Evaluation
82.9
PRIMARY
Knee Society Function Score
76.6
PRIMARY
Number of Participants With >2mm Wide at the Bone/Cement Interface or a >3 Degree or >3 mm Migration (Shift) of the Component.
PRIMARY
Safety Assessment
2; 18; 40
SECONDARY
Oxford Knee Score
36.3

Summary

The purpose of this study is to evaluate the survivorship and efficacy of the Encore 3DKnee™ system in a group of patients who will receive the 3DKnee™ as a primary (first) orthopedic implant in the knee. Each knee will be designated as a separate subject and followed for a period of 2 years.

Eligibility Criteria

Inclusion Criteria

  • This must be a primary knee replacement on this knee.
  • Have knee joint disease related to one or more of the following
  • degenerative joint disease, including osteoarthritis or traumatic arthritis
  • Avascular necrosis of the femoral condyles
  • Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy
  • Moderate valgus, varus, or flexion deformities
  • Rheumatoid arthritis
  • Patient is likely to be available for evaluation for the duration of the study
  • Able and willing to sign the informed consent and follow study procedures
  • Patient is not pregnant
  • Patient must be over 18 years of age

Exclusion Criteria

  • If there has been a total knee replacement on this knee in the past (no revisions allowed in study)
  • Infection, or history of infection, acute or chronic, local or systemic
  • Alcoholism or other addictions
  • Muscular, neurological or vascular deficiencies which compromise the affected extremity
  • Obesity
  • Insufficient bone quality
  • Loss of ligamentous structures
  • High levels of physical activity
  • Materials sensitivity
  • Prisoner
  • Mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements
  • Patient is pregnant
  • Is younger than 18 years of age
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00764673). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search